Table 1. Baseline Characteristics of the Entire Study Cohort (n=2412).
| Variables | Total (n=2412) |
|---|---|
| Clinical parameters | |
| Age, yr, median (IQR) | 64.5 (57.3-72.7) |
| <65, n (%) | 1099 (45.6) |
| ≥65, n (%) | 1313 (54.4) |
| Gender, n (%) | |
| Male | 1847 (76.6) |
| Female | 368 (15.3) |
| Missing/unknown | 197 (8.2) |
| Preoperative urine cytology, n (%) | |
| Negative | 1132 (46.9) |
| Atypical cells | 448 (18.6) |
| Positive for malignant cells | 593 (24.5) |
| Missing/unknown | 239 (10) |
| Tumor morphology, n (%) | |
| Papillary | 2060 (85.4) |
| Non-papillary (sessile/flat/mixed) | 346 (14.3) |
| Missing/unknown | 6 (0.3) |
| Tumor multiplicity, n (%) | |
| Single | 1357 (56.3) |
| Multiple (≥2) | 1031 (42.7) |
| Missing/unknown | 24 (1.0) |
| Tumor size, n (%) | |
| <3 cm | 1411 (58.5) |
| ≥3 cm | 664 (27.5) |
| Missing/unknown | 337 (14.0) |
| Pathological parameters | |
| Tumor stage, n (%) | |
| pTa | 1368 (56.7) |
| pT1/Tis | 1042 (43.2) |
| Missing/unknown | 2 (0.1) |
| Tumor grade, n (%) | |
| Low-grade | 1140 (47.3) |
| High-grade | 1143 (47.4) |
| Missing/unknown | 129 (5.3) |
| Carcinoma in situ, n (%) | |
| Absent | 2131 (88.3) |
| Present (primary or concomitant) | 200 (8.3) |
| Missing/unknown | 81 (3.4) |
| Muscle layer included, n (%) | |
| Absent | 1480 (61.4) |
| Present | 928 (38.5) |
| Missing/unknown | 4 (0.2) |
| Postoperative parameters | |
| Immediate intravesical instillation, n (%) | |
| No | 1951 (80.9) |
| Yes | 453 (18.8) |
| Missing/unknown | 8 (0.3) |
| Additional intravesical chemotherapy, n (%) | |
| No | 1983 (82.2) |
| Yes | 417 (17.3) |
| Missing/unknown | 12 (0.5) |
| BCG induction, n (%) | |
| No | 1113 (46.1) |
| Yes | 1299 (53.9) |
| BCG maintenance, n (%) | |
| No | 1573 (65.2) |
| Yes | 648 (26.8) |
| Missing/unknown | 191 (7.9) |
| Overall follow-up duration (months), median (IQR) | 37 (25-52) |
| Median first time to recurrence (months) | 10 (5-19) |
| Recurrence, n (%) | |
| No | 1543 (64.0) |
| Yes | 866 (35.9) |
| Missing/unknown | 3 (0.1) |
| Progression, n (%) | |
| No | 2263 (93.8) |
| Yes | 137 (5.7) |
| Muscle invasion | 79 |
| Distant metastasis | 58 |
| Missing/unknown | 12 (0.5) |
IQR, interquartile range; BCG, Bacillus Calmette-Guérin.